Mast cells are activated by Leishmania mexicana LPG and regulate the disease outcome depending on the genetic background of the host

Parasite Immunology

Volumn 30, Issue 8, 2008, Pages 425-434

  Villasenor Cardoso M I ^a   Salaiza, N ^a   Delgado, J ^a   Gutierrez Kobeh L ^a   Perez Torres A ^a   Becker, I ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Cytokines; Granule release; L. mexicana; Mast cells; TLR2

Indexed keywords

INTERLEUKIN 10; LIPOPHOSPHOGLYCAN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; GENETIC ANALYSIS; HOST; LEISHMANIA MEXICANA; LEISHMANIASIS; MALE; MAST CELL; MOUSE; NONHUMAN; PARASITE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL COUNT; CELL DEGRANULATION; CHEMOKINE CCL3; DISEASE MODELS, ANIMAL; GLYCOSPHINGOLIPIDS; INTERLEUKIN-10; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MALE; MAST CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RODENT DISEASES; SKIN; TOLL-LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

LEISHMANIA MEXICANA; MUS;

EID: 64549164136     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2008.01042.x     Document Type: Article

References (34)

1. Sacks D & Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2: 845-858.
2. Galli S, Kalesnikoff J, Grimbaldeston M, Piliponski AM, Williams CM & Tsai M. Mast cells as 'tunable' effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23: 749-786.
3. Galli S, Nakae S & Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005; 6: 135-142.
4. Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol 2004; 4: 787-799.
5. Maurer M, Lopez-Kostka S, Siebenhaar F, et al. Skin mast cells control T cell-dependent host defense in Leishmania major infections. FASEB J 2006; 20: 2460-2467.
6. von Stebut E. Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur J Immunol 2007; 17: 115-122.
7. Wershill BK, Theodos CM, Galli SJ & Titus RG. Mast cells augment lesion size and persistence during experimental Leishmania major infection in the mouse. J Immunol 1994; 152: 4563-4571.
8. Becker I, Salaiza N, Aguirre M, et al. Leishmania lipophos-phoglycan (LPG) activates NK cells trough toll-like receptor 2. Molec Biochem Parasitol 2003; 130: 65-74.
9. Gilead L, Bibi O & Razin E. Fibroblast induce heparin synthesis in chondroitin sulfate E containing human bone marrow-derived mast cells. Blood 1990; 76: 1188-1195.
10. McConville MJ, Bacic A, Mitchell GF & Handman E. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor. Proc Natl Acad Sci USA 1987; 84: 1829-1834.
11. Gonzalez-Espinoza C, Odom S, Olivera A, et al. Preferential signaling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells. J Exp Med 2003; 197: 1453-1465.
12. Ikeda T & Funaba M. Altered function of murine mast cells in response to lipopolysaccharide and peptidoglycan. Immunol Lett 2003; 88: 21-26.
13. Schneider E, Rolli-Derkinderen R, Arock M & Dy M. Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol 2002; 23: 255-263.
14. Mazzoni A, Young HA, Spitzer JH, Visintin A & Segal DM. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 2001; 108: 1865-1873.
15. Marshall J & Jawdat DM. Mast cells in innate immunity. J Allergy Clin Immunol 2004; 114: 21-27.
16. Feger F, Varadaradjalou S, Gao Z, Abraham SN & Arock M. The role of mast cells in the host defense and their subversion by bacterial pathogens. Trends Immunol 2002; 23: 151-158.
17. Bidri M, Vouldoukis I, Mossalayi MD, et al. Evidence for direct interaction between mast cells and Leishmania parasites. Parasite Immunol 1997; 19: 475-483.
18. Katakura K, Saito S, Hamada A, Matsuda H & Watanabe N. Cutaneous leishmaniasis in mast cell-deficient W/Wv mice. Infect Immun 1993; 61: 2242-2244.
19. Parker LC, Whyte MK, Vogel SN, Dower SK & Sabroe I. Toll-like receptor (TLR) 2 and TLR4 agonists regulate CCR expression in human monocytic cells. J Immunol 2002; 172: 4977-4986.
20. de Oliveira M, Lima M, Calheiros A, et al. Leishmania (Viannia) braziliensis: human mast cell line activation induced by logarithmic and stationary promastigote derived-lysates. Exp Parasitol 2005; 109: 72-79.
21. Fehrenbach K, Port F, Grochowy G, et al. Stimulation of mast cells via FceRI and TLR2: The type of ligand determines the outcome. Mol Immunol 2007; 44: 2087-2094.
22. Qiao H, Andrade M, Lisboa F, Morgan K & Beaven M. FceR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells. Blood 2006; 107: 610-618.
23. 2+ mobilization and G protein usage on regulation of toll-like receptor function in human and murine mast cells. Immunology 2006; 119: 412-420.
24. Olivier M, Gregory D & Forget G. Subversion mechanisms by which Leishmania parasites can escape the host immune response a signaling point of view. Clin Microbiol Rev 2005; 18: 293-305.
25. Anderson CF, Mendez S & Sacks DL. Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice. J Immunol 2005; 174: 2934-2941.
26. Pós Z, Müller K, Novalphak I, et al. Different patterns of the 1-histidine decarboxylase (HDC) gene expression in mice resistant and susceptible to experimental cutaneous leishmaniasis. Inflamm Res 2004; 53: 38-43.
27. Viana da Costa A, Huerre M, Delacre M, Auriault C, Correira JM & Verwaerde C. IL-10 leads to higher parasite persistence in a resistant mouse model of Leishmania major infection. Parasitol Int 2002; 51: 367-379.
28. Gazzinelli R, Wysocka M & Hieny S. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+T cells and accompanied by overproduction of IL-12, IFN-G, and TNF-α. J Immunol 1996; 157: 798-805.
29. Bacellar O, Lessa H, Schriefer A, et al. Up-regulation of Th1 -type responses in mucosal leishmaniasis patients. Infect Immunol 2002; 70: 6734-6740.
30. Faria D, Gollob KJ, Barbosa J, et al. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun 2005; 73: 7853-7859.
31. Azulay RD & Azulay DR. Immune-clinical-pathologic spectrum of leishmaniasis. Int J Dermatol 1995; 34: 303-307.
32. Bottrel R, Dutra WO, Martins FA, et al. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immunol 2001; 69: 3232-3239.
33. Antoniazi S, Price HP, Kropf P, et al. Chemokine gene expression in Toll-like receptor-competent and deficient mice infected with Leishmania major. Infect Immun 2004; 72: 5168-5174.
34. McFarlane E, Perez C, Charmoy M, et al. Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani. Infect Immun 2008; 76: 532-541.